Preferred Label : Dose-dense AC Followed by Paclitaxel/Pertuzumab/Trastuzumab Regimen;
NCIt synonyms : Dose-dense AC Followed by Paclitaxel-Pertuzumab-Trastuzumab; Dose-dense AC Followed by Paclitaxel/Pertuzumab/Trastuzumab; Dose-dense AC Followed by Paclitaxel-Pertuzumab-Trastuzumab Regimen; Dose-dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Pertuzumab/Trastuzumab
Regimen; Dose-dense Adriamycin/Cytoxan Followed by Taxol/Herceptin/Perjeta; Dose-Dense AC-THP; Dose-dense AC Followed by Paclitaxel/Trastuzumab/Pertuzumab Regimen;
NCIt related terms : ddAC-THP (Paclitaxel) (trastuzumab-anns); ddAC-THP (Paclitaxel) (trastuzumab-dttb); ddAC-THP (Paclitaxel); ddAC-THP (Paclitaxel) (trastuzumab-pkrb); ddAC-THP (Paclitaxel) (trastuzumab-herw); ddAC-THP (Paclitaxel) (trastuzumab-qyyp); ddAC-THP (Paclitaxel) (trastuzumab-zerc); ddAC-THP (Paclitaxel) (trastuzumab-dkst); ddAC-THP (Paclitaxel) (trastuzumab-strf);
NCIt definition : A regimen consisting of dose-dense cyclophosphamide and doxorubicin followed by paclitaxel,
pertuzumab and trastuzumab that can be used as a neoadjuvant or adjuvant treatment
for HER-2/neu-positive breast cancer.;
NCI Metathesaurus CUI : CL1664633;
Codes from synonyms : 128918; 129403; 129306; 129209; 128821; 129112; 129015; 63533; 140005;
Origin ID : C181792;
UMLS CUI : C5557267;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
